• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Insulet applauds as UK begins artificial pancreas rollout

April 4, 2024 By Sean Whooley

Insulet Omnipod 5 Abbott FreeStyle Libre 2 Plus
The Omnipod 5 with the Abbott FreeStyle Libre 2 Plus. [Image courtesy of Insulet]
Insulet (Nasdaq:PODD) expressed its excitement today as a new diabetes initiative in the UK could bring artificial pancreas’ to many with diabetes.

NHS England said tens of thousands of children and adults with type 1 diabetes in the country will receive an artificial pancreas. The initiative includes hybrid closed-loop automated insulin delivery systems like Insulet’s Omnipod 5.

The initiative, long in the works, received support from the National Institute for Health and Care Excellence (NICE). In December, NICE published guidance recommending hybrid closed-loop systems for eligible people with type 1 diabetes in England and Wales. Following that government guidance, the NHS picked up funding and shared its plans to roll out the technology in January.

NHS provided local health systems with £2.5 million ($3.2 million) to kick off the rollout.

A ‘landmark moment’ supported by companies like Insulet

“It is incredibly exciting to see hybrid closed-loop technology being rolled out on the NHS in England for people with type 1 diabetes. Diabetes is a tough and relentless condition, but these systems make a significant, life-changing difference – improving both the overall health and quality of life for people with diabetes,” Colette Marshall, Chief Executive of Diabetes UK, said.

“This really is a landmark moment and we’ll be working with the NHS and others to ensure a fair rollout that reaches people as quickly as possible.”

In a post on LinkedIn, Insulet shared its excitement around the five-year implementation strategy. Starting April 1, the timeline aims to help local systems provide automated insulin delivery systems to eligible patients.

“We applaud the collaborative efforts of NICE, NHS England and all the advocates who have tirelessly worked towards improving access to innovative technologies in diabetes care,” Insulet wrote. “This milestone underscores our shared commitment to empowering individuals with diabetes, improving health outcomes, and enhancing their quality of life through cutting-edge solutions.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Technology Tagged With: Insulet, NHS

IN CASE YOU MISSED IT

  • Tandem’s Mobi pump wins FDA clearance for 7-day tubeless wearable set
  • Senseonics delivers ‘breakout quarter’ more than doubling Eversense 365 revenue
  • Tandem Diabetes Care names successor as CEO Sheridan retires
  • MiniMed names new CMO ahead of planned retirement
  • Insulet earnings trounce Q3 estimates as it narrows guidance

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS